Login to Your Account

Hua phase Ib trial shows promise for 24-hour glucose control

By Shannon Ellis
Staff Writer

Thursday, February 12, 2015
SHANGHAI – Hua Medicine Ltd.'s sinogliatin, a fourth-generation glucokinase activator (GKA), looks set to prove it has overcome the issues of past GKA's to provide 24-hour glucose control in diabetics with the potential to improve pancreatic beta cell function.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription